Year Results: Strong Commercial Execution and Momentum in Late

Telix Pharmaceuticals reported a $38M profit after tax for H1 2026, including a $40M payment from Regeneron. Revenue rose 22% YoY to $477M, with adjusted EBITDA up 146% to $52M. R&D spending increased to $124M. The company expects 2026 revenue to exceed $1B, including the Regeneron payment.

Telix Pharmaceuticals reported H1 earnings, with precision medicine EBITDA up 26% YoY to AUD 132M. Telix Manufacturing Solutions revenue rose 10% YoY to AUD 89M, while internal revenue via RLS increased 70% to AUD 57M. The company's PSMA imaging portfolio revenue grew 9% sequentially to $202M. Telix is investing in manufacturing and distribution capacity and has regulatory updates for Pixclara and Zircaix. The BiPASS study is nearing enrollment completion, potentially doubling the PSMA imaging m

Telix Pharmaceuticals reaffirmed its FY26 guidance, projecting revenue of $950M-$970M and total income exceeding $1B, including $40M from Regeneron. H1 2026 revenue rose 22% YoY to $477M, with adjusted EBITDA up 146% to $52M. The company's strong performance is partly driven by a one-time payment from Regeneron.

Telix Pharmaceuticals reported H1 2026 revenue of $477M, up 22% YoY, with gross margin at 55%. Adjusted EBITDA rose 146% to $52M, driven by Precision Medicine sales and a $40M Regeneron collaboration payment. Profit after tax was $38M, reversing a $2M loss from H1 2025. The company expects FY 2026 revenue to exceed $1B and has established a Nasdaq at-the-market equity facility.

Telix Pharmaceuticals reported H1 2026 revenue of US$477m, up 22% YoY, and a profit after tax of US$38m. Adjusted EBITDA surged 146% to US$52m, driven by commercial execution and a US$40m payment from Regeneron. Precision Medicine segment revenue grew 27%. The company refinanced US$600m in convertible bonds and announced clinical milestones.

Telix Pharmaceuticals reported H1 2026 revenue of $477M, up 22% YoY, with gross margin at 55%. Adjusted EBITDA rose 146% to $52M, driven by strong demand and a $40M Regeneron payment. R&D investment was $124M, focusing on late-stage programs. The company refinanced $600M in convertible bonds and expects FY 2026 revenue to exceed $1B.